MedTrace Logo

A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy

NCT02264548 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-03-09

No results posted yet for this study

Summary

* evaluate the safety and toxicity profile of renal radio-ablation in the setting of metastatic renal cell carcinoma.
* to assess renal function post radio-ablation
* Primary and metastatic tumour response to radio-ablation

Conditions

Interventions

RADIATION

Radio-Ablation

Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Belal Ahmad, MD FRCPC · London Regional Cancer Program of the Lawson Health Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2020-08-04
Completion
2020-08-04

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264548 on ClinicalTrials.gov